Johnson & Johnson (JNJ)
| Previous close | 146.82 |
| Open | 146.88 |
| Bid | 145.36 x 800 |
| Ask | 145.36 x 900 |
| Day's range | 145.18 - 146.88 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,641,806 |
| Market cap | 349.888B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 19.54 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.96 (3.38%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Business Wire
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
NEW BRUNSWICK, N.J., April 16, 2024--In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B).
- Business Wire
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
NEW BRUNSWICK, N.J., April 16, 2024--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.
- PR Newswire
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy
